Procaps Group, S.A. (PROC): Price and Financial Metrics
GET POWR RATINGS... FREE!
PROC Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for PROC is -45.44 -- better than just 0.44% of US stocks.
- Equity multiplier, or assets relative to shareholders' equity, comes in at -20 for PROCAPS GROUP SA; that's greater than it is for just 1.22% of US stocks.
- As for revenue growth, note that PROC's revenue has grown -18.75% over the past 12 months; that beats the revenue growth of merely 9.01% of US companies in our set.
- Stocks that are quantitatively similar to PROC, based on their financial statements, market capitalization, and price volatility, are JILL, STCN, MKTW, HHS, and CYH.
- Visit PROC's SEC page to see the company's official filings. To visit the company's web site, go to uac-ii.
PROC Valuation Summary
- PROC's price/sales ratio is 1.8; this is 5.26% lower than that of the median Healthcare stock.
- PROC's price/sales ratio has moved NA NA over the prior 37 months.
Below are key valuation metrics over time for PROC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| PROC | 2022-11-01 | 1.8 | -27.3 | -10.6 | -193.1 |
| PROC | 2022-10-31 | 1.9 | -29.0 | -11.3 | -202.9 |
| PROC | 2022-10-28 | 1.8 | -26.8 | -10.4 | -190.8 |
| PROC | 2022-10-27 | 1.8 | -27.2 | -10.6 | -192.7 |
| PROC | 2022-10-26 | 1.8 | -27.5 | -10.7 | -194.2 |
| PROC | 2022-10-25 | 1.8 | -26.4 | -10.3 | -188.4 |
PROC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- PROC has a Quality Grade of C, ranking ahead of 50.56% of graded US stocks.
- PROC's asset turnover comes in at 1.638 -- ranking 7th of 680 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows PROC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2020-12-31 | 1.638 | 0.577 | 0.193 |
| 2020-09-30 | 0.000 | NA | 0.002 |
PROC Stock Price Chart Interactive Chart >
PROC Price/Volume Stats
| Current price | $6.61 | 52-week high | $10.49 |
| Prev. close | $6.60 | 52-week low | $5.86 |
| Day low | $6.60 | Volume | 2,800 |
| Day high | $6.70 | Avg. volume | 25,921 |
| 50-day MA | $6.93 | Dividend yield | N/A |
| 200-day MA | $8.05 | Market Cap | 745.74M |
Procaps Group, S.A. (PROC) Company Bio
Procaps Group, S.A. develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and clinical solutions. It operates in 13 countries in Latin America. The company was founded in 1977 and is based in Luxembourg City, Luxembourg
Latest PROC News From Around the Web
Below are the latest news stories about PROCAPS GROUP SA that investors may wish to consider to help them evaluate PROC as an investment opportunity.
Procaps Group Reports Third Quarter and Nine Months 2022 ResultsConstant currency Net Revenues Increased by 15% year-over-year in the 9M22 and by 11% in the 3Q22, signaling a strong demand across our businessesMIAMI and BARRANQUILLA, Colombia, Nov. 14, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended September 30, 2022 (“3Q22”) and the nine months ended September 30, 2022 (“9M22”). “Demand remains robu |
Procaps Group to Report Third Quarter and Nine Months of 2022 on November 14, 2022MIAMI and BARRANQUILLA, Colombia, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, announced that it expects to report its results for the third quarter ended September 30, 2022, after the market closes on Monday, November 14, 2022. The Company expects to host a conference call and webcast at 04 p.m. Eastern time, on November 16, 2022.To access the call, please use the following information: Date:We |
Procaps Announces ESG Commitments and Initiatives with Inaugural ReportMIAMI and BARRANQUILLA, Colombia, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced the completion of its inaugural 2021 ESG Annual Report, a comprehensive overview of environmental, social and governance metrics and corresponding strategies and initiatives for ESG priorities. Procaps commitments and initiatives include advancing a healthy, climate-resilient future, social responsibil |
Procaps Group to Participate in the BTG Pactual LatAm CEO ConferenceMIAMI and BARRANQUILLA, Colombia, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced it will participate in the BTG Pactual LatAm CEO Conference being held at the InterContinental NY Barclays Hotel October 11-13, 2022. Procaps Group Chief Executive Officer Rubén Minski, Chief Financial Officer Patricio Vargas, and Investor Relations Director Melissa Angelini will conduct in-person one- |
Procaps Group Reports Second Quarter and First Half 2022 ResultsNet Revenues Increased 14% year-over-year in the Second Quarter, with Adjusted EBITDA Margin of 24%Constant currency Net Revenues Increased by 18% year-over-year in the First Half, signaling a strong demand across our businesses MIAMI and BARRANQUILLA, Colombia, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Procaps Group S.A. (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical conglomerate, today announced its financial results for the three months ended June 30, 2022 (“2Q22 |
PROC Price Returns
| 1-mo | -2.94% |
| 3-mo | -9.45% |
| 6-mo | -22.33% |
| 1-year | -29.76% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -32.21% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...